,9 The development of current gene therapy for inherited retinal diseases in clinical trials, including RPE65-mediated inherited retinal dystrophy and choroideremia,10–13 requires the delivery of the viral vector safely into the subretinal space. This evidence concerns the gene RPE65 and choroideremia.